Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulatory News In Brief

This article was originally published in The Gray Sheet

Executive Summary

The latest FDA guidances and other regulatory updates for device makers.

You may also be interested in...



Regulatory News In Brief

FDA misses some performance goals. Device center issues ombudsman’s report. DePuy stops selling custom devices. More regulatory briefs.

Pain And Function Are Best Endpoints For Knee Cartilage Trials – FDA Panel

Joint pain and function are the most clinically meaningful efficacy outcomes and should both be used as primary endpoints for clinical trials of cellular products for treatment of knee cartilage defects, FDA's Cellular, Tissue and Gene Therapies Advisory Committee recommends

Regulatory News In Brief

UDI workshop: Planned unique device identification system is up for discussion at a Feb. 12 FDA public workshop in Gaithersburg, Md. In the Jan. 15 Federal Register notice announcing the meeting, FDA lists a set of questions it hopes to tackle at the gathering - including what types of devices should be required to be marked with bar code-like identifiers; what technologies should be employed to achieve unique device identification; and the logistical and economic impact of having to add identifiers to certain devices. The 2007 FDA Amendments Act requires FDA to develop a mandatory UDI system, but gives the agency the authority to establish alternatives and exceptions. CDRH has been in talks with manufacturers, hospitals, purchasing groups and other stakeholders for at least the past three years about developing such a system as part of its plan to improve postmarket device safety oversight (1"The Gray Sheet" Feb. 6, 2006, p. 3)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030909

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel